You are here: Home » Companies » News
Business Standard

Gland Pharma's grey market premium soars ahead of Friday's debut

The retail and HNI portion of the IPO were subscribed just 51 per cent and 24 per cent, respectively

Gland Pharma | IPO

Sundar Sethuraman  |  Thiruvananthapuram 

Market players said the episode underscores why investors should not entirely place their bets based on grey market activity

shares are in demand in the grey market. Ahead of its listing, the grey market premium (GMP) has soared from Rs 10 to Rs 140 a share — an indication that the stock could do well in the secondary market.

At the time of its initial public offering (IPO), however, there was hardly any demand. This discouraged many retail and high networth individuals (HNIs), who subsequently gave the a miss. The retail and HNI portions were subscribed just 51 per cent and 24 per cent. The Rs 6,480-crore managed to sail through solely on the back of institutional investor demand.

Market players said the episode underscores why investors should not entirely place their bets based on grey market activity. “GMP is never the right metric to apply in an First, it is illegal and not Sebi-regulated; second, it is prone to manipulation, and third, it is volatile. Investors must study the firm’s fundamentals and issue pricing before applying,” said Geetanjali Kedia, senior research analyst, SP Tulsian Investment Advisory Services.

ALSO READ: Rebound in auto industry set to brighten prospects for Kansai Nerolac

In Gland Pharma's case, the GMP at one point was Rs 200, which later fell to Rs 10.

The price band was set at Rs 1,490-1,500 per share. At the top end, the firm has a market cap of Rs 24,500 crore. It is set for its debut on Friday.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 18 2020. 17:46 IST